Browsing Tag
Brent Saunders
5 posts
Bausch + Lomb completes credit agreement amendment, reducing interest cost on $2.8bn debt
Find out how Bausch + Lomb’s $2.8B refinancing plan reshapes its debt profile, reduces interest margins, and defers amortization until 2026.
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition…
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast…
AbbVie acquisition of Allergan gets antitrust clearance from US FTC
AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade…
Allergan to acquire Bonti in strategic $195m deal to expand medical aesthetics pipeline
Irish pharmaceutical giant Allergan has announced its acquisition of Bonti, a U.S.-based aesthetic company specializing in fast-acting neurotoxin…